Prokidney Corp stock is traded at $1.11, with a volume of 401,547. It is up +4.23% in the last 24 hours and down -30.63% over the past month. ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
Previous Close:
$1.07
Open:
$1.05
24h Volume:
401,547
Relative Volume:
0.22
Market Cap:
$231.96M
Revenue:
$889.00K
Net Income/Loss:
-$156.28M
P/E Ratio:
-
EPS:
-$0.5267
Net Cash Flow:
-$150.06M
1W Performance:
-14.29%
1M Performance:
-30.63%
6M Performance:
-43.37%
1Y Performance:
-60.50%
1-Day Range:
$1.04$1.12
1-Week Range:
$0.8702$1.35
52-Week Range:
$0.8702$2.95
Prokidney Corp Stock (PROK) Company Profile
Name
Prokidney CorpSector
HealthcareIndustry
BiotechnologyPhone
336-999-7028Address
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS